---
title: "CapForce Inc. (CFOR.US)"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/CFOR.US.md"
symbol: "CFOR.US"
name: "CapForce Inc."
industry: "生物技術"
datetime: "2026-03-10T06:35:47.811Z"
locales:
  - [en](https://longbridge.com/en/quote/CFOR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CFOR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CFOR.US.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/CFOR.US.md) | [简体中文](https://longbridge.com/zh-CN/quote/CFOR.US.md)


# CapForce Inc. (CFOR.US)

## 公司概況

CapForce Inc.是一家精準醫療公司，開發和商業化分子微生物學解決方案，針對美國及國際上的危及生命的傳染病。該公司的產品包括 Unyvero 應用卡、Unyvero 系統、Acuitas AMR 基因檢測產品和 SARS CoV-2 檢測套件。它還提供實驗室服務；合作服務，包括資助的軟件安排；以及許可安排服務。此外，該公司還提供上市贊助和咨詢服務

| 項目 | 詳情 |
|------|--------|
| 行業 | 生物技術 |
| 交易所 | US Market |
| 官網 | [www.opgen.com](https://www.opgen.com) |

## 關鍵驅動因素
> *AI 分析的影響該股票表現的關鍵因素*


## Longbridge Financial Score™: A
> *Longbridge Financial Score™ — Longbridge 獨家多因子評級模型*
> 更新時間: 2026-03-10T04:30:13.000Z

**綜合: A (0.18)**

**行業**: 生物技術

| 指標 | 數值 |
|--------|-------|
| 行業排名 | 5 / 407 |
| 行業中位數 | D |
| 行業均值 | C |

- **風格**: 成長型 - 公司主要業務處在成長期的股票。
- **規模**: 小盤型 - 公司經營有較高的成長性和波動性，易於獲得較高的投資收益。

**綜合評分**: A

#### 風格得分 評分: 

| 指標 | 數值 | 評級 |
|-----------|-------|--------|
| 營業收入同比 | 610.97% |  |
| 凈利潤同比 | 167.66% |  |
| 市凈率 | 29.97 |  |
| 股息率 | 0.00% |  |

#### 規模得分 評分: 

| 指標 | 數值 | 評級 |
|-----------|-------|--------|
| 市值 | 304456950.00 |  |
| 營業收入 | 9000000.00 |  |

#### 多維評分 評分: A

| 指標 | 數值 | 評級 |
|-----------|-------|--------|
| 凈資產收益率（ROE） | 102.11% | A |
| 凈利率 | 76.04% | A |
| 毛利率 | 0.00% | E |
| 營業收入同比 | 610.97% | A |
| 凈利潤同比 | 167.66% | A |
| 總資產同比 | 131.07% | A |
| 凈資產同比 | 240.16% | A |
| 現金流凈利率 | 134.12% | C |
| 運營現金流同比 | 610.97% | A |
| 資產周轉率 | 0.99 | A |
| 資產負債率 | 19.63% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - CapForce Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "風格得分",
      "grade": "",
      "indicators": [
        {
          "name": "營業收入同比",
          "value": "610.97%",
          "rating": ""
        },
        {
          "name": "凈利潤同比",
          "value": "167.66%",
          "rating": ""
        },
        {
          "name": "市凈率",
          "value": "29.97",
          "rating": ""
        },
        {
          "name": "股息率",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "規模得分",
      "grade": "",
      "indicators": [
        {
          "name": "市值",
          "value": "304456950.00",
          "rating": ""
        },
        {
          "name": "營業收入",
          "value": "9000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "多維評分",
      "grade": "A",
      "indicators": [
        {
          "name": "凈資產收益率（ROE）",
          "value": "102.11%",
          "rating": "A"
        },
        {
          "name": "凈利率",
          "value": "76.04%",
          "rating": "A"
        },
        {
          "name": "毛利率",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "營業收入同比",
          "value": "610.97%",
          "rating": "A"
        },
        {
          "name": "凈利潤同比",
          "value": "167.66%",
          "rating": "A"
        },
        {
          "name": "總資產同比",
          "value": "131.07%",
          "rating": "A"
        },
        {
          "name": "凈資產同比",
          "value": "240.16%",
          "rating": "A"
        },
        {
          "name": "現金流凈利率",
          "value": "134.12%",
          "rating": "C"
        },
        {
          "name": "運營現金流同比",
          "value": "610.97%",
          "rating": "A"
        },
        {
          "name": "資產周轉率",
          "value": "0.99",
          "rating": "A"
        },
        {
          "name": "資產負債率",
          "value": "19.63%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## 估值分析

| 指標 | 當前值 | 行業排名 | 最高 | 中位 | 最低 |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 45.37 | 53/407 | - | - | - |
| PB | 29.97 | 426/407 | - | - | - |
| PS (TTM) | 33.83 | 221/407 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## 同業比較

| 排名 | 名稱 | 盈利 | 成長 | 營運 | 財務安全 | 現金流 | 評級 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Rigel制藥 (RIGL.US) | A | A | B | B | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## 參考連結

- [公司概況 — 簡介、高管、股東、業務構成](https://longbridge.com/zh-HK/quote/CFOR.US/overview.md)
- [財務報表 — 損益表、資產負債表、現金流、分紅方案](https://longbridge.com/zh-HK/quote/CFOR.US/norm.md)
- [相關新聞](https://longbridge.com/zh-HK/quote/CFOR.US/news.md)
- [公告 — 公司公告與監管文件](https://longbridge.com/zh-HK/quote/CFOR.US/filings.md)

---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**